Compare Stocks

→ Mysterious Gold Leverage Just Announced (From Stansberry Research) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CYTR LadRx		$0.09	$0.05 ▼ $0.86	$4.14M	N/A	99,706 shs	4,000 shs
ENTX Entera Bio	$2.00 -3.4%	$1.65	$0.52 ▼ $3.35	$57.60M	1.7	209,199 shs	117,197 shs
TROV Cardiff Oncology	$4.18 +0.2%	$16.75	$0.70 ▼ $3.46	$46.03M	1.04	648,892 shs	343,293 shs
TTNP Titan Pharmaceuticals	$6.97 -0.6%	$7.36	$5.00 ▼ $16.60	$6.34M	1.33	9,533 shs	2,582 shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CYTR LadRx	0.00%	0.00%	0.00%	0.00%	0.00%
ENTX Entera Bio	-6.76%	-6.76%	+32.69%	+141.85%	+195.67%
TROV Cardiff Oncology	-4.36%	-9.15%	-28.72%	+179.87%	+185.62%
TTNP Titan Pharmaceuticals	-3.33%	-1.83%	+1.75%	+28.60%	-55.32%

Mysterious Gold Leverage Just Announced (Ad)

World's biggest multibillionaire investor group is buying THIS by the tons Most folks have completely missed the fact that there's one group of investors so powerful they're literally buying ONE THING by the tons… Stacking it in their locked vaults on pallets in record numbers.

Find out what it is and see how you can get in with just a few dollars.

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CYTR LadRx	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ENTX Entera Bio	1.6639 of 5 stars	3.5	3.0	0.0	0.0	3.3	0.0	0.0
TROV Cardiff Oncology	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
TTNP Titan Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CYTR LadRx	N/A	N/A	N/A	N/A
ENTX Entera Bio	3.00	Buy	$10.00	400.00% Upside
TROV Cardiff Oncology	N/A	N/A	N/A	N/A
TTNP Titan Pharmaceuticals	N/A	N/A	N/A	N/A

Current Analyst Ratings

Latest CYTR, ENTX, TTNP, and TROV Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
4/2/2024	ENTX Entera Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00

(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CYTR LadRx	N/A	N/A	N/A	N/A	N/A	N/A
ENTX Entera Bio	$130K	443.08	N/A	N/A	$0.36 per share	5.56
TROV Cardiff Oncology	$250K	184.10	N/A	N/A	$0.94 per share	4.45
TTNP Titan Pharmaceuticals	$180K	35.24	N/A	N/A	$8.82 per share	0.79

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CYTR LadRx	N/A	N/A	0.00	N/A	N/A	N/A	N/A	N/A	N/A
ENTX Entera Bio	-$8.89M	-$0.31	N/A	N/A	N/A	N/A	-101.78%	-83.90%	5/3/2024 (Estimated)
TROV Cardiff Oncology	-$16.41M	-$2.80	N/A	∞	N/A	-3,688.31%	-202.00%	-122.92%	N/A
TTNP Titan Pharmaceuticals	-$5.57M	-$8.20	N/A	∞	N/A	-2,014.71%	-165.90%	-105.75%	5/20/2024 (Estimated)

Latest CYTR, ENTX, TTNP, and TROV Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
3/8/2024	Q4 2023	ENTX Entera Bio	-$0.08	-$0.07	+$0.01	-$0.07	N/A	N/A

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CYTR LadRx	N/A	N/A	N/A	N/A	N/A
ENTX Entera Bio	N/A	N/A	N/A	N/A	N/A
TROV Cardiff Oncology	N/A	N/A	N/A	N/A	N/A
TTNP Titan Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CYTR LadRx	N/A	N/A	N/A
ENTX Entera Bio	N/A	10.32	10.32
TROV Cardiff Oncology	0.12	2.37	2.37
TTNP Titan Pharmaceuticals	N/A	5.55	5.55

Ownership

Institutional Ownership

Company	Institutional Ownership
CYTR LadRx	N/A
ENTX Entera Bio	14.11%
TROV Cardiff Oncology	9.99%
TTNP Titan Pharmaceuticals	31.49%

Insider Ownership

Company	Insider Ownership
CYTR LadRx	N/A
ENTX Entera Bio	8.90%
TROV Cardiff Oncology	0.60%
TTNP Titan Pharmaceuticals	24.93%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
CYTR LadRx	N/A	45.04 million	N/A	Not Optionable
ENTX Entera Bio	17	28.80 million	26.24 million	Optionable
TROV Cardiff Oncology	N/A	11.01 million	N/A	Not Optionable
TTNP Titan Pharmaceuticals	4	910,000	686,000	Optionable

CYTR, ENTX, TTNP, and TROV Headlines

Source	Headline
	Titan Pharmaceuticals (NASDAQ:TTNP) Stock Price Passes Below Two Hundred Day Moving Average of $7.17 americanbankingnews.com - April 23 at 4:42 AM
	Titan Pharmaceuticals (NASDAQ:TTNP) Now Covered by Analysts at StockNews.com americanbankingnews.com - April 23 at 2:18 AM
	New Release: The Less Expensive Secretlab Titan Evo Lite Is Nearly as Good as the Titan Evo ign.com - April 21 at 8:14 AM
	Titan Pharmaceuticals (NASDAQ:TTNP) Now Covered by StockNews.com americanbankingnews.com - April 15 at 2:14 AM
	2005 Nissan Titan autoblog.com - March 25 at 4:09 AM
	Titan Pharmaceuticals Inc (TTNP) uk.investing.com - March 2 at 9:17 AM
	Titan Pharmaceuticals, Inc. (TN70.F) au.finance.yahoo.com - February 20 at 2:08 PM
	Titan Pharmaceuticals Inc TTNP morningstar.com - February 3 at 2:27 PM
	Titan Pharmaceuticals, Inc.: Titan Pharmaceuticals Fully Compliant With NASDAQ Listing Criteria finanznachrichten.de - January 26 at 9:07 PM
	Titan Pharmaceuticals Fully Compliant With NASDAQ Listing Criteria finance.yahoo.com - January 25 at 7:32 PM
	Titan Pharma Stock (NASDAQ:TTNP) Dividends: History, Yield and Dates benzinga.com - January 10 at 1:05 PM
	Titan Pharmaceuticals: Submission Of Matters To A Vote Of Security Holders, Financial Statements And Exhibits cbonds.com - December 30 at 10:29 AM
	Titan Pharmaceuticals, Inc.: Titan Pharmaceuticals Announces Reverse Stock Split and Ratio finanznachrichten.de - December 29 at 8:01 AM
	Barbie, the Titan submersible and everything else we Googled in 2023 washingtonpost.com - December 28 at 8:29 PM
	Titan Pharmaceuticals Announces Reverse Stock Split and Ratio finance.yahoo.com - December 28 at 8:29 PM
	Untitled Attack on Titan Codes (December 2023) twinfinite.net - December 27 at 3:54 PM
	2023 Nissan Titan XD Review autoblog.com - December 27 at 3:54 PM
	Attack on Titan Revolution Codes (December 2023) twinfinite.net - December 20 at 10:44 PM
	Titan Pharmaceuticals Announces Appointment of Dato' Seow Gim Shen and Brynner Chaim to the Company's Board of Directors finance.yahoo.com - October 16 at 8:58 PM
	More presumed human remains recovered from imploded Titan submersible today.com - October 14 at 10:10 AM
	Titan Pharmaceuticals reports $9.5M private placement of convertible preferred stock seekingalpha.com - September 18 at 11:34 AM
	Titan Pharmaceuticals Announces $9.5 Million Private Placement of Convertible Preferred Stock finance.yahoo.com - September 18 at 11:34 AM
	Unveiling Titan Pharmaceuticals (TTNP)'s Value: Is It Really Priced Right? A Comprehensive Guide finance.yahoo.com - August 28 at 5:04 PM
	Titan Pharmaceuticals: Q2 Earnings Snapshot stamfordadvocate.com - August 15 at 5:27 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

LadRx

NASDAQ:CYTR

LadRx Corp. is a biopharmaceutical research and development company, which engages in the discovery, research, and clinical development of novel anti-cancer drug candidates. It focuses on developing the Linker Activated Drug Release (LADR) technology platform, a discovery engine to help create a pipeline of anti-cancer molecules that will avoid unacceptable systemic toxicity while delivering highly potent agents directly to the tumor. The company was founded in 1985 and is headquartered in Los Angeles, CA.

Entera Bio

NASDAQ:ENTX

Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's lead product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of non-union fractures. Its other product candidate is GLP-2, which is in preclinical trial for the treatment of short bowl syndrome; and hGh for the GH deficiency. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.

Cardiff Oncology

NASDAQ:TROV

Cardiff Oncology, Inc. is an oncology therapeutics company, which engages in the development of drugs that target mitosis for the treatment of various types of cancer. The company was founded by Gabriel M. Cerrone, L. David Tomei, Samuil Umansky, and Hovsep Melkonyan in 1999 and is headquartered in San Diego, CA.

Titan Pharmaceuticals

NASDAQ:TTNP

Titan Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder. The company was founded in 1991 and is based in South San Francisco, California.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial